Seven emergency visits for alcohol intoxication—yet she and her family reported no drinking

The seventh visit

This mystery begins with a published case, not a fictional patient. In a 2024 CMAJ report, a woman in her 50s had attended emergency departments seven times over two years with features of alcohol intoxication. She said she had not consumed alcohol, and her family corroborated that account.

At the seventh presentation, the record describes slurred speech, alcohol on her breath and a serum ethanol concentration of 62 mmol/L. The laboratory result and the bedside picture agreed with each other. The history did not. That contradiction carried obvious medical, social and legal weight, but it did not by itself identify a cause.

A useful question at this point is narrower than Which rare disease is this? It is: what evidence would distinguish unreported alcohol use, an unreliable result and endogenous ethanol production without assuming any one explanation is already true?

What the case actually proved

The eventual diagnosis was auto-brewery syndrome. The label is memorable; the evidential path was less tidy. The report relied on repeated objectively raised ethanol levels, corroborated reports of no alcohol use and the clinical course. It did not describe a positive glucose challenge that settled the diagnosis.

In fact, the oral glucose challenge occurred six months later, while the patient was in remission, and was negative. Cultures were also taken after antifungal treatment and showed no fungal growth. Their timing limited what they could establish, so the case does not support naming a particular fungus—or any single organism—as the culprit.

Treatment in the report combined antifungal therapy with dietary change and follow-up. Symptoms later recurred once. Because several things changed together in one uncontrolled case, the report cannot tell us which component produced improvement, and it should not be turned into a treatment recipe.

The reveal: fermentation inside the gut

Auto-brewery syndrome describes pathological endogenous ethanol production by microbes, usually in the gastrointestinal tract. Microbial fermentation of carbohydrates can generate ethanol; in this syndrome, enough reaches the circulation to produce measurable intoxication without beverage alcohol being consumed.

That mechanism makes the contradiction biologically plausible. It does not tell us how often the syndrome occurs. Population prevalence is unknown, and much of the literature has historically consisted of case reports and small case series. An extraordinary-sounding diagnosis still requires objective, supervised evaluation and a careful differential.

The CMAJ paper also has a published correction. It changes a typographical error in the alanine aminotransferase reference range from 17–631 to 17–63 IU/L. The correction does not alter the diagnosis or story, but checking it matters: a source pack is only complete when linked corrections are read as well as the original paper.

What the 2026 cohort adds

A separate 2026 Nature Microbiology paper moved beyond a single case. The prospective observational study enrolled 22 people with documented auto-brewery syndrome and 21 unaffected household partners. It also compared some analyses with 22 age-, sex- and BMI-matched healthy controls drawn from an earlier external dataset.

In laboratory culture, stool collected from participants during a flare produced more ethanol than samples from household partners or healthy controls. This assay used subsets rather than every enrolled participant. Metagenomic work found enrichment of Proteobacteria, including Escherichia coli and Klebsiella pneumoniae, together with fermentation-related pathways. Acetate levels also correlated with blood alcohol in a small flare subset.

Those results support an important bacterial contribution in many participants. They do not prove that either named species causes every case, and Proteobacteria enrichment alone was not sufficient. Previous antifungal exposure may also have reduced fungal detection, so the study cannot close the door on fungi.

Where the new evidence stops

The cohort was small and selected, with recruitment through an advocacy organisation and support groups. Its observational design cannot establish population prevalence or turn association into causation. Four household pairs were later re-enrolled under new household IDs for repeat sampling after significant microbiome-altering treatment or a major change in symptoms. Several experiments used smaller subsets, and the healthy comparison group was external rather than contemporaneously recruited.

Funding included NIH grants and centre awards, VA Office of Research and Development, AASLD Foundation, Hellman Family Foundation and US Department of Energy support. Bernd Schnabl disclosed industry consultancy, institutional research support and founding Nterica Bio; Elizabeth Hohmann and Brigid S. Boland disclosed industry research support and/or consultancy. The remaining authors declared no competing interests.

An antibiotic reduced ethanol production in cultured stool. That is an in-vitro finding, not evidence to prescribe antibiotics to patients. The reported acetate correlation is not an established diagnostic biomarker. A single participant’s course after faecal microbiota transplantation was accompanied by changing antibiotics, bowel preparations, repeat procedures, resistant starch and a probiotic, so improvement cannot be attributed to transplantation alone.

An ongoing registered study, NCT06083142, is examining faecal microbiota transplantation in an estimated eight participants. It is active but not recruiting, open-label, single-group and Early Phase 1. ClinicalTrials.gov formally classifies its primary purpose as treatment, while the protocol describes its primary objective as evaluating safety and feasibility. It has no posted results, and primary completion is estimated for August 2029. It is an investigational pilot, not evidence that the treatment is effective.

The transferable lesson

The most useful lesson is not to hunt for auto-brewery syndrome whenever alcohol is measured. It is to notice when repeated objective data and a corroborated history remain in conflict, then test both parts of that conflict carefully. Premature certainty in either direction can miss important information.

For suspected endogenous ethanol production, the literature emphasises objective measurements and supervised conditions that exclude beverage alcohol, alongside a broader assessment for alternative explanations. A single unsupervised reading, a home experiment or a stool microbiome report cannot carry the diagnosis. No standardised diagnostic algorithm or established management guideline exists, so specialist evaluation should guide decisions, using appropriate local pathways where available.

This case is powerful because the reveal is real and the uncertainty remains visible. The 2026 cohort gives the mechanism more biological detail, but it does not supply prevalence, one universal organism, a stand-alone biomarker or a standard treatment. Good medical mystery writing should leave those boundaries intact.